

PharmaMatrix releases new data on CCI-001 in bladder and breast cancer

FOR IMMEDIATE RELEASE — May 21, 2026

PharmaMatrix Inc. today released its peer-reviewed publication on CCI-001, a novel colchicine derivative engineered for selective binding to β III-tubulin. The data describe potent activity against bladder cancer cell lines and animal models, with translational signal in breast cancer.

CCI-001 is currently in Phase 1 clinical evaluation under ClinicalTrials.gov identifier NCT04823897.

About CCI-001

CCI-001 is designed to disrupt mitosis selectively in cancer cells by targeting β III-tubulin — an isotype enriched in tumors but largely absent from healthy somatic tissue. The molecule does not appreciably cross the blood–brain barrier, addressing one of the principal limitations of conventional colchicine-based agents.

About PharmaMatrix

PharmaMatrix Inc. is a clinical-stage biotechnology company developing a new generation of targeted oncology therapies based on selective microtubule disruption. The company holds composition-of-matter patents granted by the USPTO, CIPO and EPO.

Media contact

press@pharmamatrix.com